BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT
A method of treating depression includes identifying a subject with a pain syndrome for increased responsiveness to the treatment of pain associated with the pain syndrome with botulinum toxin and locally administering a botulinum toxin subcutaneously to a face of the subject, thereby treating said pain. Identification of the pain is made prior to administering botulinum toxin for the treatment of said pain. The subject has a pain syndrome and a condition selected from the group consisting of a depressive disorder, an anxiety disorder and a sleep disorder.
1 . - 115 . canceled
116 . A method comprising the steps of:
a) identifying a subject with a pain syndrome for increased responsiveness to the treatment of pain associated with the pain syndrome with botulinum toxin; and
b) administering botulinum toxin to said subject, thereby treating said pain, wherein said identification is made prior to administering botulinurn toxin for the treatment of said pain and further wherein the subject has a pain syndrome and a condition selected from the group consisting of a depressive disorder, an anxiety disorder and a sleep disorder.
117 . The method of claim 116 , wherein the depressive disorder in said subject is identified by a medical history of depression.
118 . The method of claim 116 , wherein the anxiety disorder in said subject is identified by a medical history of anxiety.
119 . The method of claim 116 , wherein the sleep disorder in said subject is identified by a medical history of sleep disturbance.
120 . The method of claim 117 , wherein the presence of said depressive disorder in said subject is predictive of an increased responsiveness to the treatment of said pain syndrome with botulinum toxin.
121 . The method of claim 118 , wherein the presence of said anxiety disorder in said subject is predictive of an increased responsiveness to the treatment of said pain syndrome with botulinum toxin.
122 . The method of claim 119 , wherein the presence of said sleep disorder in said subject is predictive of an increased responsiveness to the treatment of said pain syndrome with botulinum toxin.
123 . The method of claim 116 , wherein the botulinum toxin is any form of immunotypes A, B, C, D, E, F, or G.
124 . Method of claim 123 which involves a formulation devoid of human blood products.
125 . The method of claim 116 , wherein the pain syndrome is any one or more of the pain syndromes selected from the group consisting of: myofacial pain, migraine headache, post-operative wound pain, sinusitis-related headaches, muscle tension headaches, post-traumatic headaches, cluster headaches, temporal mandibular joint syndrome, fibromyalgia, atypical facial pain, post incisional wound pain, cervical radiculopathy, and whiplash.
126 . A method for identifying a subject with a migraine who has increased responsiveness to the treatment with botulism toxin of the pain associated with migraine, comprising the step of:
identifying a subject with increased responsiveness to the treatment of migraine associated pain with botulism toxin prior to administering the botulism toxin by selecting a subject from a group consisting of subjects who exhibit a depressive disorder, an anxiety disorder or a sleep disorder.
127 . A method for identifying a subject with a headache syndrome who has increased responsiveness to the treatment of migraine associated pain with botulism toxin, comprising the step of
identifying the subject prior to administering the botulism toxin for the treatment of the headache syndrome, wherein the subjects-are selected from the group of subjects consisting of subjects having a depressive disorder, an anxiety disorder or a sleep disorder.
128 . The method of claim 127 , wherein the headache syndrome is migraine.
129 . The method of claim 127 , wherein the headache syndrome is tension headache.
130 . The method of claim 127 , wherein the headache syndrome is temporal mandibular joint syndrome.
131 . The method of claim 127 , wherein the headache syndrome is sinusitis related headache.